BBLG logo

Bone Biologics Stock Price

Symbol: NasdaqCM:BBLGMarket Cap: US$4.4mCategory: Pharmaceuticals & Biotech

BBLG Share Price Performance

US$2.74
-11.48 (-80.73%)
US$2.74
-11.48 (-80.73%)
Price US$2.74

BBLG Community Narratives

There are no narratives available yet.

BBLG Community Fair Values

    Recent BBLG News & Updates

    No updates

    Bone Biologics Corporation Key Details

    US$0

    Revenue

    US$0

    Cost of Revenue

    US$0

    Gross Profit

    US$7.5m

    Other Expenses

    -US$7.5m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -4.66
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Bone Biologics Corporation Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About BBLG

    Founded
    2004
    Employees
    2
    CEO
    Jeffrey Frelick
    WebsiteView website
    www.bonebiologics.com

    Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

    U.S. Market Performance

    • 7 Days: -1.2%
    • 3 Months: 13.1%
    • 1 Year: 22.8%
    • Year to Date: 7.3%
    Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading